13 results about "Y nucleoside" patented technology

Disclosed herein are improved methods and compositions of de novo synthesis of nucleic acids by cyclic extension using nucleotides that have an N-linked or O-linked scar or protecting group, and subsequent removal of the scar or protecting group. During polymerase-nucleotide conjugate-based polynucleotide synthesis or after the synthesis is completed, nucleobases having a scar from linker cleavage can be converted back into native form by removal of the scars from the nucleobases. Secondary structure formation in the nascent chain, which may inhibit extension reactions, is suppressed by the use of monomers with protected nucleobases that prevent Watson-Crick base pairing and / or other structures. After the synthesis is completed, the nucleobases can be converted back into native form by palladium-based removal of the protecting groups.

The present disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in the treatment of infectious diseases, viral infections, and cancer, wherein the base of the nucleotide or nucleoside contains at least one thiol, thione, or thioether.

This disclosure related to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the nucleotide or nucleoside is a compound having the formula:

Provided are: a method for producing a compound useful as a nucleotide prodrug; a compound useful as a starting material or an intermediate of the production method; and a nucleotide prodrug precursor.　A method for producing a compound according to the present invention comprises: an aryloxylation step for reacting a compound (1) with a phenol compound ArOH to obtain a compound (2); an oxidative halogenation step for oxidatively halogenating the compound (2) with a halogenating agent to obtain a compound (3); and an amination step for reacting the compound (3) with a compound (5) to obtain a compound (4). In the formula, R11-R15 are a hydrogen atom, etc., R1 is an optionally substituted aryl group, R2-R4 are a hydrogen atom, etc., R5 is an optionally substituted alkyl group, R6 is an amino acid side chain, etc., Ar is an optionally substituted aryl group, X is a halogenyl group, A- is a counter anion, and Bs represents a nucleic acid base optionally having a protecting group.

This disclosure relates to nucleotide and nucleoside therapeutic compositions and their use in treating infectious diseases, viral infections and cancer, wherein the bases of said nucleotide or nucleoside contain at least one thiol, thion, or thioether.

The present disclosure provides single-stranded or double-stranded interfering RNA molecules (e.g., siRNAs) that exhibit improved gene silencing. The present disclosure provides siRNA molecules having a fixed nucleobase region. For example, the antisense strand of the siRNA molecule may have a nucleobase region containing one or more mismatches relative to a target mRNA molecule. Alternatively or additionally, the antisense strand may contain a nucleobase region having a sequence independent of the target mRNA. An immobilization region may be included within a protruding end region of the antisense strand. The siRNA molecule may contain a specific pattern of nucleoside modification and a nucleoside-to-nucleoside linkage modification, as a pharmaceutical composition comprising the siRNA molecule. The siRNA molecule may be a branched siRNA molecule, such as a two-branched, three-branched or four-branched siRNA molecule. The disclosed siRNA molecules may further be characterized by a 5 '-phosphorus stabilizing moiety and / or a hydrophobic moiety. In addition, the present disclosure provides methods for delivering siRNA molecules of the present disclosure to a subject, such as the central nervous system of a subject identified as having a neurodegenerative disease.

In one aspect, the invention relates to a TnpB variant polypeptide comprising a Deinococcus radiodurans (ISDra2) TnpB polypeptide sequence and, separated by a peptide linker, a nuclear localization module comprising at least two nuclear localization sequences (NLS) separated by a first peptide linker. A second aspect of the invention relates to a DNA editing polypeptide comprising the TnpB variant polypeptide according to the invention, wherein the TnpB variant polypeptide comprises a nuclease deactivating mutation, and a nucleoside deaminase. The invention further relates to a nucleic acid sequence encoding a polypeptide according to the invention, and to a virus comprising the nucleic sequence.

Disclosed herein compositions comprising at least two siRNAs connected to each other by a multivalent linker, wherein at least one of the at least two siRNAs comprise at least one modified inter-nucleoside linkage, at least one modified nucleoside, or a combination thereof. The at least one siRNA provided herein can be used to target and reduce expression of a gene encoding angiopoietin-like protein, such as angiopoietin-like protein 4 (also referred to as ANGPLT4). Various modifications to inter-nucleoside linkage and nucleoside are also disclosed. The compositions provided herein can be used to treat diseases, conditions, and reduce or maintain body weight in a subject.

Embodiments of the present disclosure relate to modified adenosine nucleosides and nucleotides. Also provided herein are methods and kits for sequencing applications using such nucleotides.

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether. The nucleotide and nucleoside therapeutic compositions can include at least one second antiviral agent, such as an antiviral agent that treats or prevents enterovirus infections.

This disclosure relates to therapeutic compositions of nucleotides and nucleosides and their use in the treatment of infectious diseases, viral infections and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

Embodiments of the present disclosure relate to modified adenosine nucleosides and nucleotides. Also provided herein are methods and kits for sequencing applications using such nucleotides.